Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a
Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies
Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments
https://finance.yahoo.com/news/editas-medicine-shoreline-biosciences-enter-120000080.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.